Iranian Journal of Virology
مجله ویروس شناسی ایران
Iran J Virol
Medical Sciences
http://journal.isv.org.ir
1
admin
1735-5680
2588-5030
10.21859/isv
en
jalali
1390
2
1
gregorian
2011
5
1
5
2
online
1
fulltext
en
Construction of Influenza A/H1N1 Virosomal Nanobioparticles
عمومى
General
پژوهشي
Original article
Background and Aims: Influenza is one of the main respiratory infections of humans, responsible for 300,000–500,000 annual deaths world-wide. Vaccination is one of the best ways to prevent infections including influenza. Influenza virosomes are virus-like particles, which retain the cell binding and membrane fusion properties of the native virus, but lack the ribonucleoprotein (RNP). A virosomal influenza vaccine has recently been commercially available in Europe (Inflexal V®). The virosome is prepared by membrane solubilization and reconstitution. A new method based on dialyzable detergent has been developed to produce virosomes from an A/H3N2 influenza virus. Methods: In this study attempt was made to construct a virosomal nanobioparticle of influenza A/ PR8 (H1N1). The Madine-Darby Canine kidney (MDCK) cell line was cultured and infected with influenza virus strain A/PR8 and the culture media were harvested and the virus was purified by ultracentrifugation and concentrated by ultrafiltration. Purified influenza virus was treated with 1, 2-dicaproyl-sn-glycero-3-phosphocholine (DCPC) as a solubilizing detergent to resolve the viral envelope. Ribonucleoprotein was sedimented by ultracentrifugation and the supernatant consisting phospholipids and glycoproteins of influenza virus was reconstituted by removal of DCPC using overnight dialysis against Hank's Buffered Saline (HBS) solution. Results: Finally, the empty influenza virus envelope, called virosome, was observed by transmission electron microscopy (TEM). The size of these particles was estimated to be 50-100 nm. Conclusion: Virosome has been used as a new vaccine formulation and since it is a nontoxic adjuvant carrier it can be used to improve the present commercialized and new vaccines.
Influenza Virus, Virosome, Nanobioparticles
13
18
http://journal.isv.org.ir/browse.php?a_code=A-10-1-44&slc_lang=en&sid=1
M
Noori
10031947532846003681
10031947532846003681
No
Department of Biology, Alzahra University, Tehran, Iran
Sh
Ghorbani
10031947532846003682
10031947532846003682
No
Department of Biology, Alzahra University, Tehran, Iran
A
Jamali
10031947532846003683
10031947532846003683
No
Influenza Unit, Pasteur Institute of Iran, Tehran, Iran
M
Shenagari
10031947532846003684
10031947532846003684
No
Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
H
Hashemi
10031947532846003685
10031947532846003685
No
Department of Medical Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
R
Saghiri
10031947532846003686
10031947532846003686
No
Biochemistry Department, Pasteur Institute of Iran, Tehran, Iran
N
Kazemi
10031947532846003687
10031947532846003687
No
Influenza Unit, Pasteur Institute of Iran, Tehran, Iran
M
Tavassoti-Kheiri
10031947532846003688
10031947532846003688
Yes
Influenza Unit, Pasteur Institute of Iran, Tehran, Iran